IPP Bureau

HRV Pharma & SMS LifeSciences form strategic partnership for orphan and niche APIs
HRV Pharma & SMS LifeSciences form strategic partnership for orphan and niche APIs

By IPP Bureau - January 21, 2026

Senores Pharmaceuticals reports stellar Q3 FY26 growth; PAT surges 105%
Senores Pharmaceuticals reports stellar Q3 FY26 growth; PAT surges 105%

By IPP Bureau - January 21, 2026

In Q3 FY26, Senores posted consolidated revenue of Rs. 175 crore, up 64% year-on-year.

Medico Remedies secures government supply order of Rs. 73.23 Cr
Medico Remedies secures government supply order of Rs. 73.23 Cr

By IPP Bureau - January 21, 2026

Medico Remedies has secured the order to supply Azithromycin 500gm (tablets) to Uttar Pradesh Medical Supplies Corporation Limited

FDA go ahead for Eli Lilly’s therapy for hard-to-treat ovarian cancer
FDA go ahead for Eli Lilly’s therapy for hard-to-treat ovarian cancer

By IPP Bureau - January 21, 2026

Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells

Max Institute partners with Intuitive Surgical to expand robotic-assisted surgery in India
Max Institute partners with Intuitive Surgical to expand robotic-assisted surgery in India

By IPP Bureau - January 21, 2026

The collaboration will focus on enhancing surgeon capabilities, developing structured training pathways, and promoting the adoption of robotic-assisted surgery in both routine and complex procedures

AstraZeneca to withdraw Nasdaq listings ahead of NYSE direct listing
AstraZeneca to withdraw Nasdaq listings ahead of NYSE direct listing

By IPP Bureau - January 21, 2026

The move follows AstraZeneca’s previously announced plan to complete a direct listing of its Ordinary Shares and debt securities on the New York Stock Exchange

Sigachi Industries achieves key R&D milestone in Cystic Fibrosis APIs
Sigachi Industries achieves key R&D milestone in Cystic Fibrosis APIs

By IPP Bureau - January 21, 2026

The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments

Tatva Chintan Pharma Chem posts consolidated Q3 FY26 at Rs. 15.16 Cr
Tatva Chintan Pharma Chem posts consolidated Q3 FY26 at Rs. 15.16 Cr

By IPP Bureau - January 21, 2026

Tatva Chintan Pharma Chem has reported total income of Rs. 133.06 crore during the period ended December 31, 2025

Kindeva appoints David Stevens as new CEO
Kindeva appoints David Stevens as new CEO

By IPP Bureau - January 20, 2026

Stevens succeeds Milton Boyer, who has stepped down as CEO but will remain closely involved with the business as an independent member of Kindeva’s Board of Directors

Alto Neuroscience bags new US patent for depression drug ALTO-207
Alto Neuroscience bags new US patent for depression drug ALTO-207

By IPP Bureau - January 20, 2026

ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease

Avalon clinches majority investment to expand future of diagnostic intelligence
Avalon clinches majority investment to expand future of diagnostic intelligence

By IPP Bureau - January 20, 2026

The new investment will fuel expansion of Avalon's Diagnostic Intelligence capabilities

Symeres rehires Jurgen Berendsen as CFO amid strategic growth push
Symeres rehires Jurgen Berendsen as CFO amid strategic growth push

By IPP Bureau - January 20, 2026

Berendsen brings over 15 years of financial leadership experience spanning professional services and international trade

IDT and Ansa Biotechnologies join forces to push limits of DNA synthesis
IDT and Ansa Biotechnologies join forces to push limits of DNA synthesis

By IPP Bureau - January 20, 2026

The collaboration aims to accelerate the delivery of challenging DNA motifs with speed, precision, and reliability

China nod to two Sanofi drugs for rare and complex conditions
China nod to two Sanofi drugs for rare and complex conditions

By IPP Bureau - January 20, 2026

Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM

AbbVie’s Epcoritamab shows progression-free survival gain in relapsed/refractory DLBCL trial
AbbVie’s Epcoritamab shows progression-free survival gain in relapsed/refractory DLBCL trial

By IPP Bureau - January 20, 2026

Improvements were also seen in complete response rates, duration of response, and time to next treatment

Latest Stories

Interviews

Packaging